Literature DB >> 3720553

[Tolerance development during a 1-week course of dobutamine treatment].

H H Erlemeier, W Kupper, C W Hamm, W Bleifeld.   

Abstract

UNLABELLED: Eleven patients with chronic heart failure (NYHA stage III or IV) were given dobutamine infusions over 7 days, mean dose 6.2 +/- 2.2 micrograms/kg X min. The patients were pretreated with digitalis, diuretics, and vasodilators. Haemodynamic parameters were measured prior to infusion, 30 minutes and 7 days thereafter as well as 24 hours after the end of therapy. Before and after the 7-day therapy a two-dimensional echocardiogram was taken. In four patients, the protocol had to be discontinued prematurely for technical or medical reasons.
RESULTS: Arterial blood pressure, body weight, fractional shortening and end-diastolic diameter of the left ventricle were not changed significantly. Cardiac index rose acutely and returned to initial values after 7 days. Total peripheral resistance, which was initially significantly reduced, again rose after infusion over 7 days. Permanent reduction in pulmonary artery wedge pressure, even one day after the end of therapy, was observed in three patients showing a left-ventricular end-diastolic wall thickness greater than 7 mm. However, in patients whose wall thickness was less than 7 mm, there was a rise in pulmonary artery wedge pressure accompanied by a fall in cardiac index even below initial values.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3720553     DOI: 10.1055/s-2008-1068574

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

1.  Ketotifen and cardiovascular effects of xamoterol following single and chronic dosing in healthy volunteers.

Authors:  R F Schäfers; I Karl; K Mennicke; A E Daul; T Philipp; O E Brodde
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

2.  Intermittent infusion of dobutamine in the therapy of severe congestive heart failure--long-term effects and lack of tolerance.

Authors:  H H Erlemeier; W Kupper; W Bleifeld
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.